Header_Image_Investors
Corporate Profile

Theseus Pharmaceuticals is passionately committed to improving the lives of cancer patients by working to outsmart cancer resistance. Led by a team of targeted oncology pioneers with a proven track record developing and commercializing cancer therapeutics, the Company is developing next-generation tyrosine kinase inhibitors (TKIs): “pan-variant” targeted therapies that address all major drug resistant mutations. Theseus believes a pan-variant approach is the most effective way to address cancer resistance.

The Company’s lead program, THE-630, is a pan-variant KIT inhibitor for patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor to address C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).

Corporate Presentation
Stock Price
NASDAQTHRX
Recent News Releases from Theseus
Oct 3, 2022

THE-349 is a fourth-generation, potent and selective, small molecule designed to inhibit all major classes of EGFR activating and resistance mutations Preclinical data to be presented at the 34th...

Sep 6, 2022

Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery,...

Aug 11, 2022

THE-630 Phase 1/2 clinical trial enrolling patients; initial data expected in Q2 2023 Nomination of development candidate for fourth-generation epidermal growth factor receptor (EGFR) inhibitor...

View All

Recent Events
Wednesday, September 14, 2022
3:30pm EDT
Tuesday, September 13, 2022
12:00pm EDT
Wednesday, August 10, 2022
10:20am EDT

View all